AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05083468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
Study NCT06543043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Administered orally.
Study NCT06543043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.
Study NCT06543043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Administered orally.
Study NCT05446181 — intervention group
Intervention type: BEHAVIORAL
Intervention: Perioperative delirium
Description: Perioperative delirium
Study NCT05446181 — intervention group
Intervention type: PROCEDURE
Intervention: Hip surgery
Description: Orthopedic hip joint surgery under spinal anesthesia
Study NCT06537596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Description: Single administration of 89Zr-TLX300-CDx
Study NCT04766203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment of REDS using a holistic treatment arm
Description: This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
Study NCT05598385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open cannulation
Description: A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.
Study NCT05598385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous cannulation
Description: Cannulation is performed through a suture-mediated closure system.
Study NCT06568484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay)~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)
Study NCT06568484 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, rifapentine
Description: CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (tuberculin skin test \[TST\] or interferon-gamma release assay \[IGRA\])~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)~1HP: 1 month of daily isoniazid (H) and rifapentine (P) (28 doses)
Study NCT06568484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)
Study NCT05748665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Using remimazolam for induction of general anesthesia
Study NCT05748665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate
Description: Using etomidate for induction of general anesthesia
Study NCT06413212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
Description: Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
Study NCT05548010 — intervention group
Intervention type: OTHER
Intervention: No intervention as this is an observational study
Description: No intervention
Study NCT05868382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study NCT05868382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.4
Description: Sterile liquid for injection
Study NCT05868382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.6
Description: Sterile liquid for injection
Study NCT04802174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
Study NCT04802174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
Study NCT05227703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231 15 mg
Description: CVL-231 15 mg, oral (tablet), once per day for 6 weeks
Study NCT05227703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Required CVL-231 30 mg
Description: CVL-231 30 mg, oral (tablet), once per day for 6 weeks
Study NCT05227703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Study NCT05847283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone priming ovarian stiumulation protocol
Description: Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
Study NCT05847283 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GnRH antagonist protocol
Description: In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
Study NCT05273437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System identification experiment for physical activity
Description: The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
Study NCT06616636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezatapopt
Description: Given orally with food
Study NCT06594848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black rice extract
Description: Black rice extract is rich in a specific type of anthocyanins, cyanidin. It has been shown by our group that cyanidin-rich food can have beneficial health effects
Study NCT06594848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is composed by maltodextrin and food colorant
Study NCT06663358 — intervention group
Intervention type: DRUG
Intervention: Pegunigalsidase-alfa
Description: Administered via intravenous (IV) infusion under conditions of routine clinical care
Study NCT06669104 — intervention group
Intervention type: DEVICE
Intervention: Medtronic Hugo™ surgical robotic system
Description: undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
Study NCT06616636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth
Study NCT06691308 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: WL276 CAR-T cells
Description: This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses
Study NCT06692179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orally administered preparation of fecal microbiota (MTP-101P)
Description: As per standard of care, patients will receive MBP and OA the day prior to surgery as well as IV antibiotics at the time of surgery. MTP-101P will be given 48 hours after the administration of the dose of IV antibiotics to avoid the undesired bactericidal effects of antibiotics on the bacterial load from MTP-101P.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT05837117 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient's Perspective
Description: Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being
Study NCT05408975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation
Description: Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
Study NCT05408975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial direct current stimulation
Description: Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
Study NCT04556890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS/Active iTBS DFPLC/Sham Pain M1
Description: Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
Study NCT04556890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS/Active iTBS
Description: Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT05451329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VVN539 Ophthalmic Solution 0.02%
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study NCT05451329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VVN539 Ophthalmic Solution 0.04%
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study NCT05451329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VVN539 Ophthalmic Solution Vehicle
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study NCT05274698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT05727904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel plus Pembrolizumab
Description: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
Study NCT05727904 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab with Optional Crossover Period
Description: Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2.
Study NCT05423730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Wine
Description: One serving (5 ounces) of white wine daily for 3 weeks
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
Study NCT05423730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Juice
Description: One serving (6 ounces) of white grape juice daily for 3 weeks
Study NCT06576427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertex Pulmonary Embolectomy System
Description: Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
Study NCT05736224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
Study NCT05736224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UV Light
Description: UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
Study NCT05736224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV Light
Description: UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
Study NCT05274698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.
Description: Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel
Study NCT06613958 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity timing
Description: The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.
Study NCT06613581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based follow-up
Description: Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines
Study NCT06207318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: The intervention will be based on Acceptance and Commitment Therapy (ACT). ACT is an empirically-based therapeutic approach that focuses on psychological flexibility, acceptance, and the reduction of experiential avoidance. It encourages individuals to change their relating to thoughts and experiences and act in accordance with their values.
Study NCT05274698 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.
Description: Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel
Study NCT06575309 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: The procedures added as part of this research are 6 blood samples, the volumes of which do not exceed the volume authorized in the order of February 17, 2021, i.e. 27mL.
Study NCT05411614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip
Description: Minimally-invasive epicardial ablation +/- left atrial appendage exclusion using an epicardial clip, combined with endocardial radiofrequency catheter ablation
Study NCT05411614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial Catheter Ablation
Description: Standard percutaneous endocardial catheter ablation of atrial fibrillation